BioLineRx Ltd. (TLV:BLRX)
1.200
-0.100 (-7.69%)
Apr 3, 2026, 1:44 PM IDT
BioLineRx Revenue
In the year 2025, BioLineRx had annual revenue of $1.18M USD, down -95.92%. BioLineRx had revenue of $194.00K in the quarter ending December 31, 2025, a decrease of -98.35%.
Revenue
$1.18M
Revenue Growth
-95.92%
P/S Ratio
8.33
Revenue / Employee
$49.17K
Employees
24
Market Cap
31.33M ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.18M | -27.76M | -95.92% |
| Dec 31, 2024 | 28.94M | 24.14M | 502.92% |
| Dec 31, 2023 | 4.80M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evogene | 12.28M |
| Clal Biotechnology Industries | 11.55M |
| XTL Biopharmaceuticals | 3.26M |
| Can-Fite BioPharma | 1.29M |
| Geffen Residence & Renewal | 78.00K |
| BioLight Life Sciences | 21.00K |
BioLineRx News
- 9 days ago - BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) - PRNewsWire
- 12 days ago - Earnings Scheduled For March 23, 2026 - Benzinga
- 12 days ago - BioLineRx Reports 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 12 days ago - BioLineRx (BLRX) and Others Set to Announce Earnings - GuruFocus
- 19 days ago - BioLineRx to Report 2025 Annual Results on March 23, 2026 - PRNewsWire
- 4 months ago - BioLineRx (BLRX) Surpasses Q3 EPS Estimates Despite Revenue Shortfall - GuruFocus
- 4 months ago - BioLineRx (BLRX) Q3 Revenue Declines Amid New Joint Venture - GuruFocus
- 4 months ago - BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire